Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Monogenic disease analysis establishes that fetal insulin accounts for half of human fetal growth
Alice E. Hughes, … , Sarah E. Flanagan, Andrew T. Hattersley
Alice E. Hughes, … , Sarah E. Flanagan, Andrew T. Hattersley
Published February 21, 2023
Citation Information: J Clin Invest. 2023;133(6):e165402. https://doi.org/10.1172/JCI165402.
View: Text | PDF
Research Letter Development Endocrinology

Monogenic disease analysis establishes that fetal insulin accounts for half of human fetal growth

  • Text
  • PDF
Abstract

Authors

Alice E. Hughes, Elisa De Franco, Rachel M. Freathy, Fetal Insulin and Growth Consortium, Sarah E. Flanagan, Andrew T. Hattersley

×

Figure 1

The effect of absent fetal insulin on pre- and postnatal growth in humans.

Options: View larger image (or click on image) Download as PowerPoint
The effect of absent fetal insulin on pre- and postnatal growth in human...
(A) Birth weights in individuals without fetal insulin. Light green, INS (n = 21); blue, pancreatic agenesis (n = 43). Normal growth median, dark pink; the shaded pink area indicates ±2 SDs (INTERGROWTH-21st, refs. 1, 8). The relationship between birth weight without fetal insulin and gestational age is shown by the line-of-best fit (solid blue) and 95% prediction intervals (dashed blue) from a univariable linear regression model. (B) Adjusted birth weight (40 weeks) in the absence of insulin in female (light gray, n = 31) and male (dark gray, n = 33) individuals. Center line, median; box limits, IQR; whiskers, 1.5 × IQR. Unpaired, 2-tailed Student’s t test was used. (C and D) Growth in first 4 years following insulin treatment in individuals with a recessive INS mutation. (C) Weight (orange circles, n = 10) and (D) length/height (green triangles, n = 7 birth, n = 9 postnatal), with large symbols showing the median. Measurements were standardized (SDS) for sex and gestational age/age (9). Absent data points for individuals were approximated from available data using linear interpolation.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts